[go: up one dir, main page]

MA32712B1 - Anticorps anti-vegf/anti-ang-2 bispecifique - Google Patents

Anticorps anti-vegf/anti-ang-2 bispecifique

Info

Publication number
MA32712B1
MA32712B1 MA33772A MA33772A MA32712B1 MA 32712 B1 MA32712 B1 MA 32712B1 MA 33772 A MA33772 A MA 33772A MA 33772 A MA33772 A MA 33772A MA 32712 B1 MA32712 B1 MA 32712B1
Authority
MA
Morocco
Prior art keywords
ang
vegf
bispecific antibody
against human
dual
Prior art date
Application number
MA33772A
Other languages
Arabic (ar)
English (en)
Inventor
Monika Baehner
Ulrich Brinkmann
Guy Georges
Remko Albert Griep
Sabine Imhof-Jung
Anita Kavlie
Hubert Kettenberger
Christian Klein
Joerg Thomas Regula
Wolfgang Schaefer
Juergen Michael Schanzer
Werner Scheuer
Stefan Seeber
Markus Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41364494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32712(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32712B1 publication Critical patent/MA32712B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)

Abstract

La présente invention porte sur des anticorps bispécifiques dirigés contre VEGF humain et contre ANG-2 humain, sur des méthodes pour leur production, sur des compositions pharmaceutiques contenant lesdits anticorps et sur leurs utilisations.
MA33772A 2008-10-08 2011-04-13 Anticorps anti-vegf/anti-ang-2 bispecifique MA32712B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08017607 2008-10-08
EP08021834 2008-12-16
PCT/EP2009/007182 WO2010040508A1 (fr) 2008-10-08 2009-10-07 Anticorps anti-vegf/anti-ang-2 bispécifiques

Publications (1)

Publication Number Publication Date
MA32712B1 true MA32712B1 (fr) 2011-10-02

Family

ID=41364494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33772A MA32712B1 (fr) 2008-10-08 2011-04-13 Anticorps anti-vegf/anti-ang-2 bispecifique

Country Status (32)

Country Link
US (6) US8268314B2 (fr)
EP (3) EP2781526A1 (fr)
JP (2) JP5368570B2 (fr)
KR (2) KR20130118994A (fr)
CN (2) CN102753577B (fr)
AR (1) AR073775A1 (fr)
AU (1) AU2009301431B8 (fr)
BR (1) BRPI0919663A2 (fr)
CA (1) CA2739122C (fr)
CL (1) CL2011000769A1 (fr)
CO (1) CO6351794A2 (fr)
CR (1) CR20110166A (fr)
CY (1) CY1115030T1 (fr)
DK (1) DK2344537T3 (fr)
EC (1) ECSP11010969A (fr)
ES (1) ES2455217T3 (fr)
HK (1) HK1199265A1 (fr)
HR (1) HRP20140376T1 (fr)
IL (1) IL211729A (fr)
MA (1) MA32712B1 (fr)
MX (1) MX2011003190A (fr)
MY (1) MY178926A (fr)
NZ (1) NZ591602A (fr)
PE (1) PE20110425A1 (fr)
PL (1) PL2344537T3 (fr)
PT (1) PT2344537E (fr)
RU (2) RU2542382C2 (fr)
SG (1) SG195536A1 (fr)
SI (1) SI2344537T1 (fr)
TW (2) TWI458492B (fr)
WO (1) WO2010040508A1 (fr)
ZA (1) ZA201102203B (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051438A2 (fr) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation de rgm et de ses modulateurs
CA2624562A1 (fr) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
EP2033971A1 (fr) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Domaines de protéines recombinantes des protéines morphogénétiques osseuses (BMP) de la famille des Repulsive Guidance Molecule (RGM) et leurs fragments fonctionnels ainsi que leur utilisation
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
JP5774851B2 (ja) 2008-01-03 2015-09-09 ザ スクリプス リサーチ インスティテュート モジュラー認識ドメインを介してターゲティングする抗体
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102227447A (zh) 2008-10-02 2011-10-26 新兴产品开发西雅图有限公司 Cd86拮抗物多靶点结合蛋白
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP2414391B1 (fr) 2009-04-02 2018-11-28 Roche Glycart AG Anticorps multispécifiques renfermant des anticorps complets et des fragments fab monocaténaires
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
CA2777242A1 (fr) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Agents de liaison bispecifiques qui ciblent la signalisation igf-1r et erbb3, et leurs utilisations
DK2510001T3 (en) * 2009-12-08 2016-02-29 Abbvie Deutschland MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
CN105693861A (zh) * 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2593142B8 (fr) 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Conjugués d'anticorps multifonctionnels
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
KR20130126576A (ko) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
WO2012010550A1 (fr) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Méthode d'identification d'un patient présentant une probabilité accrue de répondre à un traitement anticancéreux
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102372778B (zh) * 2010-08-19 2015-06-17 上海抗体药物国家工程研究中心有限公司 抗人vegf和opn双特异性抗体、其制备方法及用途
WO2012025530A1 (fr) * 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
EP2686334B2 (fr) 2011-03-16 2020-07-01 F.Hoffmann-La Roche Ag Chromatographie échangeuse d'ions à sélectivité améliorée pour séparation de monomères polypeptidiques, d'agrégats et de fragments par modulation de la phase mobile
BR112013023653A2 (pt) 2011-03-17 2016-12-13 Univ Ramot anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2837169C (fr) 2011-05-24 2021-11-09 Zyngenia, Inc. Complexes multispecifiques contenant un peptide de liaison de l'angiopoietin-2 et utilisations connexes
CN109608543A (zh) * 2011-10-20 2019-04-12 艾斯巴技术-诺华有限责任公司 稳定的多抗原结合抗体
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN102936277B (zh) * 2011-12-29 2014-10-01 北京五康新兴科技有限公司 人血管内皮生长因子抗原表位及其表位疫苗
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
US20150110788A1 (en) * 2012-03-06 2015-04-23 Galaxy Biotech, Llc Bispecific antibodies with an fgf2 binding domain
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2839019A4 (fr) 2012-04-20 2016-03-30 Emergent Product Dev Seattle Polypeptides se liant à cd3
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
CN104471397B (zh) 2012-07-13 2018-03-23 弗·哈夫曼-拉罗切有限公司 用于检测多特异性结合物的方法
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
KR102205077B1 (ko) * 2012-08-31 2021-01-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｖｅｇｆ-특이적 에피토프 및/또는 안지오포이에틴-2-특이적 에피토프를 함유하는 ｄｎａ 백신
EP2900261A1 (fr) * 2012-09-28 2015-08-05 Boehringer Ingelheim International GmbH Combinaisons pharmaceutiques comprenant des liants doubles angiopoïétine-2/dll4 et des agents anti-vegf-r
MX2015003894A (es) * 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf.
CN104755489B (zh) 2012-10-30 2019-01-15 弗·哈夫曼-拉罗切有限公司 使用双级切线流超滤纯化多肽
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
RU2019108429A (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
SG10201800492PA (en) * 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
US10184010B2 (en) 2013-07-09 2019-01-22 Ablbio Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof
KR102060187B1 (ko) 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
PT3041513T (pt) 2013-09-08 2020-09-07 Kodiak Sciences Inc Conjugados de polímeros zwiteriónicos com fator viii
EP3055329B1 (fr) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Anticorps à chaîne variable légère commune échangés dans un domaine multispécifique
CN103604923B (zh) * 2013-10-22 2015-05-13 卫生部北京医院 检测抗甲状腺过氧化物酶和甲状腺球蛋白的天然双特异性抗体的试剂盒
KR102178323B1 (ko) 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
CN105829889B (zh) * 2013-12-13 2019-03-08 豪夫迈·罗氏有限公司 用于测定多价、多特异性分子的生物活性的基于spr的桥接测定法
PE20160753A1 (es) * 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
KR20160104636A (ko) * 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체
AR100271A1 (es) 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
JP7100425B2 (ja) * 2014-06-28 2022-07-13 コディアック サイエンシーズ インコーポレイテッド デュアルｐｄｇｆ／ｖｅｇｆアンタゴニスト
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
BR112017006591A2 (pt) * 2014-11-06 2018-01-16 Hoffmann La Roche polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
CN107108720A (zh) * 2014-11-06 2017-08-29 豪夫迈·罗氏有限公司 具有改变的FCRN结合的Fc区变体及其使用方法
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
MX2017005642A (es) * 2014-11-10 2017-07-24 Hoffmann La Roche Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
WO2016075036A1 (fr) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anticorps anti-pdgf-b et leurs méthodes d'utilisation
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CN104818295A (zh) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 制备和筛选表达双特异性抗体细胞株的方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017020001A2 (fr) * 2015-07-29 2017-02-02 Allergan, Inc. Anticorps contenant seulement une chaîne lourde contre ang-2
CN108350063A (zh) * 2015-09-14 2018-07-31 星系生物科技责任有限公司 针对血管生成因子的高度有效的单克隆抗体
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
EP3150637A1 (fr) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Anticorps multi-specifiques
WO2017055539A1 (fr) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps multispécifiques
CN108699162A (zh) * 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
CN108712911A (zh) * 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
KR102293755B1 (ko) * 2016-01-06 2021-08-24 오더-메이드 메디컬 리서치 인코포레이티드 고친화성 항vegf 항체
EP3401330A4 (fr) 2016-01-06 2019-09-18 Order-Made Medical Research Inc. Anticorps empêchant la liaison vegf - nrp1
CN109069638B (zh) * 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
CN109415435B (zh) * 2016-07-04 2024-01-16 豪夫迈·罗氏有限公司 新型抗体形式
WO2018017714A1 (fr) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Anticorps monoclonaux humanisés ciblant ve-ptp (hptp-ss)
CA3034574A1 (fr) * 2016-08-23 2018-03-01 Medimmune Limited Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
WO2018122053A1 (fr) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Formulation d'anticorps anti-angiopoïétine-2
PE20191758A1 (es) 2017-03-22 2019-12-12 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
CN108659112B (zh) * 2017-03-30 2021-01-26 上海市同济医院 一种非对称双特异性抗体
AU2018253176B2 (en) * 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
BR112019022074A2 (pt) 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
WO2019169341A1 (fr) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Anticorps anti-il-6 et constructions de fusion et conjugués associés
CA3095373A1 (fr) * 2018-04-13 2019-10-17 Affimed Gmbh Constructions de fusion d'anticorps entrant en contact avec des cellules nk
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
EP3805757A4 (fr) * 2018-06-04 2022-03-23 Chugai Seiyaku Kabushiki Kaisha Procédé permettant de détecter un complexe
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2020006516A1 (fr) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antagonistes des régulateurs de points de contrôle immunitaires antitumoraux
SG11202013217PA (en) * 2018-07-03 2021-01-28 Catalent Pharma Solutions Llc Multifunctional protein molecules comprising decorin and use thereof
AU2019314999B2 (en) * 2018-08-03 2025-12-04 Amgen Inc. Antibody constructs for CLDN18.2 and CD3
WO2020037309A1 (fr) * 2018-08-17 2020-02-20 Trican Biotechnology Co., Ltd. Protéine de fusion anti-angiogenèse et ses utilisations
US11066476B2 (en) 2018-09-14 2021-07-20 Shanghai tongji hospital Asymmetric bispecific antibody
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
WO2020254351A1 (fr) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Procédé de génération d'une cellule exprimant un anticorps multivalent, multispécifique par intégration ciblée de multiples cassettes d'expression dans une organisation définie
BR112021025462A2 (pt) 2019-06-19 2022-02-01 Hoffmann La Roche Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição
EP4010370A1 (fr) * 2019-08-06 2022-06-15 F. Hoffmann-La Roche AG Traitement personnalisé de maladies ophtalmologiques
CN115947846A (zh) 2019-09-12 2023-04-11 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4061852A4 (fr) * 2019-11-21 2024-03-13 Unity Biotechnology Anticorps dirigés contre tie-2 et méthodes d'utilisation
EP4126949A1 (fr) 2020-03-24 2023-02-08 Genentech, Inc. Agents de liaison à tie2 et leurs procédés d'utilisation
EP4180453A4 (fr) 2020-07-07 2023-12-27 Kanaph Therapeutics Inc. Protéines de fusion comprenant un inhibiteur de la voie du complément et un inhibiteur de l'angiogenèse, et leur utilisation
CN115803010A (zh) * 2020-07-09 2023-03-14 豪夫迈·罗氏有限公司 浓缩的蛋白质组合物、它们的制备及其用途
AU2021304372A1 (en) * 2020-07-10 2023-03-02 Biomolecular Holdings Llc Tetrahedral antibodies
CN114106190B (zh) 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
CA3193163A1 (fr) 2020-09-04 2022-03-10 F. Hoffmann-La Roche Ag Anticorps se liant a vegf-a et a ang2 et methodes d'utilisation
WO2022057888A1 (fr) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène bispécifique se liant spécifiquement au vegf et à l'ang-2
TW202233668A (zh) * 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2022256820A1 (fr) * 2021-06-03 2022-12-08 Gensun Biopharma Inc. Antagonistes multispécifiques
IL309035A (en) * 2021-06-04 2024-02-01 Innovent Biologics Suzhou Co Ltd A bispecific binding molecule that binds to VEGF and ANG2 and its use
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
WO2023215783A1 (fr) * 2022-05-04 2023-11-09 Kephera Diagnostics, Llc Méthode pour détecter la maladie de lyme
WO2024065268A1 (fr) * 2022-09-28 2024-04-04 科兴生物制药股份有限公司 Anticorps ou fragment de liaison à l'antigène capable d'identifier ang-2, et anticorps bispécifique pour identifier simultanément vegf et ang-2
WO2024076993A2 (fr) * 2022-10-03 2024-04-11 Therini Bio, Inc. PROTÉINES DE LIAISON À UN ANTIGÈNE MULTI-SPÉCIFIQUES QUI SE LIENT AU DOMAINE γC HUMAIN DE LA FIBRINE OU DU FIBRINOGÈNE ET AU FACTEUR DE CROISSANCE ENDOTHÉLIALE VASCULAIRE ET MÉTHODES D'UTILISATION
WO2025178426A1 (fr) * 2024-02-23 2025-08-28 주식회사 알토스바이오로직스 Nouvel anticorps anti-ang-2 et ses utilisations
WO2025219504A1 (fr) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Traitement de maladies ophtalmologiques
WO2025252203A1 (fr) * 2024-06-06 2025-12-11 江苏恒瑞医药股份有限公司 Utilisation d'un conjugué anticorps-médicament anti-nectine-4 pour le traitement d'une tumeur

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0462246A4 (en) 1989-11-07 1992-11-25 Bristol-Myers Squibb Company Oligomeric immunoglobulins
AU8506991A (en) 1990-08-31 1992-03-30 Bristol-Myers Squibb Company Homoconjugated immunoglobulins
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5729577A (en) 1996-05-21 1998-03-17 Motorola, Inc. Signal processor with improved efficiency
US5917811A (en) 1996-05-22 1999-06-29 Qualcomm Incorporated Method and apparatus for measurement directed hard handoff in a CDMA system
ATE501170T1 (de) 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
CA2297692A1 (fr) 1997-08-18 1999-02-25 Innogenetics N.V. Molecules de fixation d'interferon-gamma permettant de traiter des chocs septiques, la cachexie, des troubles immunitaires et des problemes dermatologiques
CA2317727C (fr) 1998-01-23 2013-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Derives d'anticorps a usages multiples
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP2857516B1 (fr) 2000-04-11 2017-06-14 Genentech, Inc. Anticorps multivalents et leurs utilisations
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
CA2387338C (fr) * 2001-05-23 2009-07-28 Suncor Stainless, Inc. Systeme de rails a montage rapide
WO2003020906A2 (fr) 2001-08-31 2003-03-13 Abmaxis, Inc. Conjugues de proteines multivalentes ayant des domaines de liaison de ligand multiples de recepteurs
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2005000900A1 (fr) 2003-05-30 2005-01-06 Genentech, Inc. Traitement au moyen d'anticorps anti-vegf
CA2527694C (fr) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Banque de fab pour la preparation de fab anti-vegf et antirabique
EP1641827A2 (fr) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Molecules de liaison modifiees comprenant des peptides de connexion
CA2531118C (fr) 2003-07-01 2013-01-08 Immunomedics, Inc. Porteuses polyvalentes d'anticorps bispecifiques
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
EP1786918A4 (fr) 2004-07-17 2009-02-11 Imclone Systems Inc Nouveau anticorps bispecifique tetravalent
CA2577133A1 (fr) 2004-08-19 2006-03-23 Genentech, Inc. Variants de polypeptides dotes d'une fonction effectrice modifiee
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2006093794A1 (fr) 2005-02-28 2006-09-08 Centocor, Inc. Compositions de liaison proteinique de forme heterodimerique
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
WO2007044887A2 (fr) 2005-10-11 2007-04-19 Transtarget, Inc. Procede de production d'une population homogene d'anticorps bispecifiques tetravalents
US20090123474A1 (en) 2005-12-15 2009-05-14 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
HUE029445T2 (en) 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CA2683801A1 (fr) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
EP2197490A2 (fr) 2007-08-28 2010-06-23 Biogen Idec MA, Inc. Compositions qui se lient à de multiples épitopes de igf-1r
CN103554215B (zh) 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
BRPI0819693A2 (pt) 2007-11-30 2020-08-18 Glaxo Group Limited Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
KR20110013409A (ko) 2008-05-23 2011-02-09 삼성전자주식회사 항체-펩티드 융합 상승체
HRP20170615T1 (hr) 2008-06-25 2017-07-28 Esbatech, An Alcon Biomedical Research Unit Llc Stabilna i topiva protutijela koja inhibiraju vegf
AR073538A1 (es) 2008-09-03 2010-11-17 Genentech Inc Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
MX2011013781A (es) 2009-06-17 2012-05-29 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos.
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
CN103237810A (zh) 2010-02-23 2013-08-07 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
MY186099A (en) 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists

Also Published As

Publication number Publication date
US20210047394A1 (en) 2021-02-18
PT2344537E (pt) 2014-05-09
TW201334788A (zh) 2013-09-01
US20120321627A1 (en) 2012-12-20
CN102753577B (zh) 2014-07-16
US20150004166A1 (en) 2015-01-01
ZA201102203B (en) 2011-12-28
EP2344537A1 (fr) 2011-07-20
JP2012504943A (ja) 2012-03-01
US8703130B2 (en) 2014-04-22
MY178926A (en) 2020-10-23
AU2009301431A8 (en) 2013-11-14
AR073775A1 (es) 2010-12-01
EP2344537B1 (fr) 2014-01-29
HK1199265A1 (en) 2015-06-26
HRP20140376T1 (hr) 2014-05-23
ECSP11010969A (es) 2011-05-31
KR101345522B1 (ko) 2013-12-31
KR20110055726A (ko) 2011-05-25
TWI458492B (zh) 2014-11-01
NZ591602A (en) 2012-06-29
WO2010040508A8 (fr) 2011-02-24
PL2344537T3 (pl) 2014-07-31
PE20110425A1 (es) 2011-07-01
WO2010040508A1 (fr) 2010-04-15
IL211729A0 (en) 2011-06-30
EP2781526A1 (fr) 2014-09-24
SG195536A1 (en) 2013-12-30
JP5368570B2 (ja) 2013-12-18
CL2011000769A1 (es) 2011-09-16
MX2011003190A (es) 2011-04-27
US20230399391A1 (en) 2023-12-14
CN103936860A (zh) 2014-07-23
US20100111967A1 (en) 2010-05-06
BRPI0919663A2 (pt) 2015-12-01
WO2010040508A9 (fr) 2011-04-21
IL211729A (en) 2015-10-29
JP2014039549A (ja) 2014-03-06
RU2640253C2 (ru) 2017-12-27
CN102753577A (zh) 2012-10-24
DK2344537T3 (da) 2014-02-10
US8268314B2 (en) 2012-09-18
SI2344537T1 (sl) 2014-05-30
CO6351794A2 (es) 2011-12-20
US20170369566A1 (en) 2017-12-28
AU2009301431B8 (en) 2013-11-14
TW201018485A (en) 2010-05-16
TWI393571B (zh) 2013-04-21
ES2455217T3 (es) 2014-04-15
KR20130118994A (ko) 2013-10-30
HK1172354A1 (en) 2013-04-19
RU2542382C2 (ru) 2015-02-20
CA2739122A1 (fr) 2010-04-15
RU2014149553A (ru) 2016-06-27
EP2792687B1 (fr) 2018-05-16
CY1115030T1 (el) 2016-12-14
US9708396B2 (en) 2017-07-18
EP2792687A1 (fr) 2014-10-22
CR20110166A (es) 2011-06-03
AU2009301431A1 (en) 2010-04-15
RU2011117410A (ru) 2012-12-20
AU2009301431B2 (en) 2013-10-31
CA2739122C (fr) 2018-05-15

Similar Documents

Publication Publication Date Title
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
UA110932C2 (uk) Біспецифічне двовалентне антитіло анти-vegf/анти-ang-2
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MA34091B1 (fr) Anticorps anti-cd40
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
EA201790757A1 (ru) Связывающие антиген cd27l белки
EP2254911A4 (fr) Anticorps anti-c5ar humanisés
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
LT2013016A (lt) Aktyvuotos-potencijuotos formos antikūno poveikio padidinimo būdas
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
FI20135143A7 (fi) Menetelmä vasta-aineen aktivoidun potensoidun muodon tehon lisäämiseksi
MY171206A (en) A method of increasing the effect of an activated-potentiated form of an antibody
TH0801006146A (th) แอนติ-vegf แอนติบอดี